{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:19:49Z","timestamp":1791443989086,"version":"4.3.3"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023976","name":"Zorgverzekeraars Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010763","name":"Zorginstituut Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100218","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:16:37Z","timestamp":1773357397000},"page":"100218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological boosting of azacitidine\/venetoclax in acute myeloid leukemia"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-1618","authenticated-orcid":false,"given":"Niels","family":"Westra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4264-4658","authenticated-orcid":false,"given":"Elena Ropero","family":"Cerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6335-1891","authenticated-orcid":false,"given":"Edwin","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5390-2791","authenticated-orcid":false,"given":"Marjolijn N.","family":"Lub-de Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-765X","authenticated-orcid":false,"given":"Jos G. W.","family":"Kosterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana A.","family":"Chitu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-4901","authenticated-orcid":false,"given":"Emanuele","family":"Ammatuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8847-2704","authenticated-orcid":false,"given":"Saskia K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Cuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Cruijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-4446","authenticated-orcid":false,"given":"Maarten M. F.","family":"Corsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Alhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwine","family":"Tick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-8555","authenticated-orcid":false,"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-645X","authenticated-orcid":false,"given":"Carolien M.","family":"Woolthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-5858","authenticated-orcid":false,"given":"Thijs H.","family":"Oude Munnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100218_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.bneo.2026.100218_bib2","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.bneo.2026.100218_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2026.100218_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100218_bib5","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.bneo.2026.100218_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2014 the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bneo.2026.100218_bib7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/dmd.116.071613","article-title":"Metabolism and disposition of a novel BCL-2 inhibitor venetoclax in humans and characterization of its unusual metabolites","volume":"45","author":"Liu","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.bneo.2026.100218_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100218_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00228-017-2403-3","article-title":"Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics","volume":"74","author":"Freise","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.bneo.2026.100218_bib12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/pharmaceutics15041149","article-title":"Pharmacokinetic boosting of kinase inhibitors","volume":"15","author":"Westra","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bneo.2026.100218_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107373","article-title":"Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: a phase 2 study","volume":"133","author":"De la Garza-Salazar","year":"2023","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bcp.15590","article-title":"Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: a proof-of-concept case study","volume":"89","author":"De la Garza-Salazar","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100218_bib15","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jphp.12820","article-title":"Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat","volume":"69","author":"Hossain","year":"2017","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100218_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer","volume":"1","author":"Xu","year":"2010","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"10.1016\/j.bneo.2026.100218_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.bneo.2026.100218_bib18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/0284186X.2017.1311024","article-title":"Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal","volume":"56","author":"Lubberman","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.bneo.2026.100218_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lungcan.2022.07.012","article-title":"Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: the OSIBOOST trial","volume":"171","author":"van Veelen","year":"2022","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2026.100218_bib20","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/jcph.70085","article-title":"Osimertinib cost minimization in non-small cell lung cancer (NSCLC) treatment: hypothesis generation for a population pharmacokinetic approach for equivalent dose optimization of osimertinib in combination with cobicistat","volume":"65","author":"Westra","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bneo.2026.100218_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113346","article-title":"Pharmacokinetic boosting of olaparib: a randomised, cross-over study (PROACTIVE-study)","volume":"194","author":"Overbeek","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bneo.2026.100218_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221142277","article-title":"Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)","volume":"14","author":"van der Togt","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/FTD.0000000000001283","article-title":"Midazolam boosting with cobicistat in a patient with drug-resistant epilepsy and focal status epilepticus","volume":"47","author":"Van Den Born-Bondt","year":"2025","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cts.12921","article-title":"Pharmacoenhancement of low crizotinib plasma concentrations in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer using the CYP3A inhibitor cobicistat","volume":"14","author":"Hohmann","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.bneo.2026.100218_bib25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2026.100218_bib26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/2767-9764.CRC-21-0076","article-title":"Intentional modulation of ibrutinib pharmacokinetics through CYP3A inhibition","volume":"1","author":"Eisenmann","year":"2021","journal-title":"Cancer Res Commun"},{"issue":"6","key":"10.1016\/j.bneo.2026.100218_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment\u2013mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.bneo.2026.100218_bib29","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.18632\/oncotarget.3614","article-title":"Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes","volume":"6","author":"Alonso","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bneo.2026.100218_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.70179","article-title":"Validation of a LC-MS\/MS assay for rapid and simultaneous quantification of cobicistat and venetoclax in human plasma and serum","volume":"39","author":"Westra","year":"2025","journal-title":"Biomed Chromatogr"},{"issue":"5","key":"10.1016\/j.bneo.2026.100218_bib31","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ajhg.2025.03.003","article-title":"Low-cost generation of clinical-grade, layperson-friendly pharmacogenetic passports using oligonucleotide arrays","volume":"112","author":"Lanting","year":"2025","journal-title":"Am J Hum Genet"},{"issue":"8","key":"10.1016\/j.bneo.2026.100218_bib33","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/jcph.2248","article-title":"Pooled population pharmacokinetic analyses of venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials","volume":"63","author":"Gong","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100218_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.bneo.2026.100218_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122476","article-title":"A fast and simple method for the simultaneous analysis of midazolam, 1-hydroxymidazolam, 4-hydroxymidazolam and 1-hydroxymidazolam glucuronide in human serum, plasma and urine","volume":"1162","author":"Wessels","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"10.1016\/j.bneo.2026.100218_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.bneo.2026.100218_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2025.1664425","article-title":"Real-world experience of venetoclax target dosing with concomitant posaconazole in adult patients with acute myeloid leukemia","volume":"4","author":"Freeman","year":"2025","journal-title":"Front Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hon.2964","article-title":"Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"40","author":"Brackman","year":"2022","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-024-04673-5","article-title":"Overexposure to venetoclax is associated with prolonged duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia","volume":"94","author":"Kobayashi","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100218_bib40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/hon.2646","article-title":"Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis","volume":"37","author":"Agarwal","year":"2019","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100218_bib41","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/cancers17071138","article-title":"Impact of venetoclax treatment schedule on hematologic recovery and treatment response in AML patients unfit for intensive chemotherapy","volume":"17","author":"Sch\u00fcpbach","year":"2025","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.bneo.2026.100218_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70049","article-title":"Outcomes with venetoclax 50 mg, hypomethylating agents, and voriconazole or posaconazole in acute myeloid leukemia","volume":"6","author":"Diebold","year":"2025","journal-title":"EJHaem"},{"issue":"9","key":"10.1016\/j.bneo.2026.100218_bib43","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jcph.70025","article-title":"Quantifying the effect of posaconazole on venetoclax metabolism in Chinese patients with hematologic diseases","volume":"65","author":"Sun","year":"2025","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100218_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40265-013-0160-x","article-title":"Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bneo.2026.100218_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100805","article-title":"Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"\u0160imoni\u010dov\u00e1","year":"2022","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.bneo.2026.100218_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043553","article-title":"Solute carrier family 29A1 mediates in vitro resistance to azacitidine in acute myeloid leukemia cell lines","volume":"24","author":"Kutyna","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bneo.2026.100218_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114636","article-title":"The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins","volume":"162","author":"Loos","year":"2023","journal-title":"Biomed Pharmacother"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:27:32Z","timestamp":1779294452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000294"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100218","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological boosting of azacitidine\/venetoclax in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100218"}}